Pfizer withdraws all lots of Oxbryta (voxelotor) for the treatment of sickle cell disease

Pfizer Inc.  announced  that it is voluntarily withdrawing all lots of Oxbryta voxelotor) for the treatment of sickle cell disease (SCD) at this time, in all markets where it is approved. Pfizer is also discontinuing all active voxelotor clinical trials and expanded access programs worldwide.

Pfizer’s decision is based on the totality of clinical data that now indicates the overall benefit of Oxbryta no longer outweighs the risk in the approved sickle cell patient population. The data suggest an imbalance in vaso-occlusive crises and fatal events which require further assessment.

Pfizer has notified regulatory authorities about these findings and its decision to voluntarily withdraw Oxbryta  from the market and discontinue distribution and clinical studies while further reviewing the available data and investigating the findings.